Impaired Th17 polarization of phenotypically naive CD4+ T-cells during chronic HIV-1 infection and potential restoration with early ART

Table 3 Clinical parameters of chronically HIV-infected subjects under long-term viral suppressive ART (CI on ART)

Subjects	CD4 counts ¹	Nadir CD4 counts ¹	CD8 counts ¹	Plasma viral load ²	Time since infection ³	ART	ART initiation ⁴	Age ⁵
CI 01	463	36	757	50	152	3TC-Efavirenz	105	52
CI 02	n.a.	350	n.a.	50	94	Kivexa-Efavirenz	24	30
CI 03	616	486	330	40	186	Truvada-Viracept	153	29
CI 04	651	219	409	40	76	Kivexa-Nevirapine	19	39
CI 05	358	231	283	40	155	Atripla	142	48
CI 06	748	20	964	40	165	Truvada-Norvir-Reyataz	134	50
CI 07	517	223	259	40	82	Kivexa-Sustiva	39	35
CI 08	269	263	282	50	n.a.	n.a.	n.a.	47
CI 09	569	299	462	50	111	Darunavir-Raltegravir	105	50
CI 10	391	181	620	50	165	Dalavirdine-Kivexa	34	46
CI 11	847	110	944	40	168	Reyataz-Kivexa	116	62
CI 12	498	201	531	40	213	Darunavir-Raltegravir-Intelence-Ritonavir	155	62
CI 13	833	486	445	40	213	Truvada-Isentress	212	31
CI 14	886	301	579	40	60	Truvada-Isentress	15	54
CI 15	824	251	900	40	58	Atripla	11	31
CI 16	617	24	1,272	40	157	Kivexa-Efavirenz	3	54
CI 17*	776	407	478	40	289	Atripla	231	24
CI 18	277	228	909	40	11	Complera	2	23
CI 19	459	n.a	545	40	215	n.a.	n.a.	48
Median	592	230	538	40	156	Yes	105	47

¹, cells/μl; ², HIV RNA copies per ml plasma (log₁₀); ³, months; ART, antiretroviral therapy; ⁴, months post-infection; ⁵, years; n.a., information not available on ART duration and regimen; *, subject infected at birth.

ISSN: 1742-4690